Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients

Journal of Viral Hepatitis

Volumn 21, Issue 6, 2014, Pages 416-423

  Ronzoni, L ^a   Aghemo, A ^a   Rumi, M G ^a   Prati, G ^a   Colancecco, A ^a   Porretti, L ^a   Monico, S ^a   Colombo, M ^a   Cappellini, M D ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

anaemia; erythropoiesis; haemolysis; hepatitis C virus; pegylated interferon; ribavirin

Indexed keywords

HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CD34 SELECTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; EX VIVO STUDY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CULTURE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETICULOCYTE COUNT; TREATMENT DURATION; ADOLESCENT; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; FEMALE; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; ERYTHROID CELLS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; YOUNG ADULT;

EID: 84901019336     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12158     Document Type: Article

References (22)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
3. Feld JJ, Hoofnagle JH,. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436 (7053): 967-972. (Pubitemid 41191673)
4. Feld JJ, Lutchman GA, Heller T, et al,. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139 (1): 154-162.
5. Hézode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360 (18): 1839-1850.
6. Aghemo A, Rumi MG, Monico S, et al,. Ribavirin impairs salivary gland function during combination treatment with pegylated interferon alfa-2a in hepatitis C patients. Hepat Mon 2011; 11 (11): 918-924.
7. Sulkowski MS, Cooper C, Hunyady B, et al,. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8 (4): 212-223.
8. De Franceschi L, Fattovich G, Turrini F, et al,. Hemolytic anemia induced by Ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004. (Pubitemid 30169949)
9. Fellay J, Thompson AJ, Ge D, et al,. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464 (7287): 405-408.
10. Thompson AJ, Fellay J, Patel K, et al,. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139 (4): 1181-1189.
11. Feld JJ, Nanda S, Huang Y, et al,. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46 (5): 1548-1563. (Pubitemid 350155537)
12. Jayaram HN, Cooney DA, Gruseh M, Krupitza G,. Consequences of IMP dehydrogenase inhibition and its relationship to cancer and apoptosis. Curr Med Chem 1999; 6: 561-574. (Pubitemid 29328001)
13. Su WC, Liu WL, Cheng CW, et al,. Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett 2009; 583 (17): 2793-2798.
14. Ronzoni L, Bonara P, Rusconi D, Frugoni C, Libani I, Cappellini MD,. Erythroid differentiation and maturation from peripheral CD34+ cells in liquid culture: cellular and molecular characterization. Blood Cells Mol Dis 2008; 40 (2): 148-155. (Pubitemid 351227426)
15. Wang W, Hedstrom L,. Kinetic mechanism of human inosine 5-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry 1997; 36: 8479-8483. (Pubitemid 27305130)
16. Liu Y, Bohn SA, Sherley JL,. Inosine-5-monophosphate dehydrogenase is a rate determining factor for p53-dependent growth regulation. Mol Biol Cell 1998; 9: 15-28. (Pubitemid 28065278)
17. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
18. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. NEJM 2011; 364: 2405-2416.
19. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
20. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
21. Gane EJ, Stedman CA, Hyland RH, et al,. Once daily PSI-7977 plus Rbv: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 [Abstract]. Hepatology 2011; 54 (4): 76A.
22. Brunati C, Cappellini MD, De Feo T, et al,. Uremic inhibitors of erythropoiesis: a study during treatment with recombinant human erythropoietin. Am J Nephrol 1992; 12 (1-2): 9-13.